Skip to main content

Advertisement

SpringerLink
Log in

Monocyte chemotactic protein-1 and CC chemokine receptor 2 polymorphisms and prognosis of renal cell carcinoma

  • Research Article
  • Published:
Tumor Biology

Abstract

Monocyte chemoattractant protein-1 (MCP-1) and its receptor CC chemokine receptor 2 (CCR2) play a major role in inflammation and proliferation of cancers. We investigated a possible association between polymorphisms in MCP-1 and CCR2 genes (MCP-1 -2518A/G and CCR2 190G/A or V64I) and the risk as well as prognosis of renal cell carcinoma (RCC). Genotypes were determined by polymerase chain reaction–restriction fragment length polymorphism in 416 RCC cases and 458 age-matched healthy controls. Frequency of MCP-1 2518GG genotype for cases and controls was 0.384 and 0.286, respectively; individuals carrying the GG genotype had a 1.89-fold increased risk of RCC than those with AA genotype (95 % confidence interval [CI] 1.24–2.81, p = 0.002; data were adjusted for age and sex). Frequency of CCR2 190AA (64I/64I) genotype for cases and controls was 0.175 and 0.076, respectively; subjects having AA genotype had a 2.68-fold increased risk of RCC compared to those with the wild-type GG genotype (95 %CI 1.71–4.17, p = 4.3 × 10−6; data were adjusted for age and sex). When analyzing the survival rate of RCC, patients with MCP-1 -2518GG genotype revealed significantly shorter survival time compared to cases with MCP-1 -2518AA and AG genotypes (p = 0.003). Similarly, RCC cases carrying CCR2 190AA genotype showed significantly shorter survival rate than patients with GG or GA genotypes (p < 0.001). These data suggested that MCP-1 -2518A/G and CCR2 190G/A polymorphisms are new risk factors for RCC and could be used as prognostic markers for this malignancy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004;6:17–32.

    Article  CAS  PubMed  Google Scholar 

  2. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol. 2000;27:177–86.

    CAS  PubMed  Google Scholar 

  3. Yoshimura T, Robinson EA, Tanaka S, Appella E, Kuratsu J, Leonard EJ. Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants. J Exp Med. 1989;169:1449–59.

    Article  CAS  PubMed  Google Scholar 

  4. Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29:313–26.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  5. Barna BP, Pettay J, Barnett GH, Zhou P, Iwasaki K, Estes ML. Regulation of monocyte chemoattractant protein-1 expression in adult human non-neoplastic astrocytes is sensitive to tumor necrosis factor (TNF) or antibody to the 55-kDa TNF receptor. J Neuroimmunol. 1994;50:101–7.

    Article  CAS  PubMed  Google Scholar 

  6. Brown Z, Strieter RM, Neild GH, Thompson RC, Kunkel SL, Westwick J. IL-1 receptor antagonist inhibits monocyte chemotactic peptide 1 generation by human mesangial cells. Kidney Int. 1992;42:95–101.

    Article  CAS  PubMed  Google Scholar 

  7. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, et al. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A. 1990;87:5134–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  8. Zhang J, Patel L, Pienta KJ. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 2010;21:41–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Zhang J, Lu Y, Pienta KJ. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst. 2010;102:522–8.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Craig MJ, Loberg RD. CCL2 (monocyte chemoattractant protein-1) in cancer bone metastases. Cancer Metastasis Rev. 2006;25:611–9.

    Article  CAS  PubMed  Google Scholar 

  11. Lu Y, Cai Z, Galson DL, Xiao G, Liu Y, George DE, et al. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate. 2006;66:1311–8.

    Article  CAS  PubMed  Google Scholar 

  12. Mazzucchelli L, Loetscher P, Kappeler A, Uguccioni M, Baggiolini M, Laissue JA, et al. Monocyte chemoattractant protein-1 gene expression in prostatic hyperplasia and prostate adenocarcinoma. Am J Pathol. 1996;149:501–9.

    PubMed Central  CAS  PubMed  Google Scholar 

  13. Chetcuti A, Margan S, Mann S, Russell P, Handelsman D, Rogers J, et al. Identification of differentially expressed genes in organ-confined prostate cancer by gene expression array. Prostate. 2001;47:132–40.

    Article  CAS  PubMed  Google Scholar 

  14. Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, et al. CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia. 2006;8:578–86.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Li X, Loberg R, Liao J, Ying C, Snyder LA, Pienta KJ, et al. A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res. 2009;69:1685–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia. 2007;9:556–62.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  17. Hu H, Sun L, Guo C, Liu Q, Zhou Z, Peng L, et al. Tumor cell-microenvironment interaction models coupled with clinical validation reveal CCL2 and SNCG as two predictors of colorectal cancer hepatic metastasis. Clin Cancer Res. 2009;15:5485–93.

    Article  CAS  PubMed  Google Scholar 

  18. Rovin BH, Lu L, Saxena R. A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. Biochem Biophys Res Commun. 1999;259:344–8.

    Article  CAS  PubMed  Google Scholar 

  19. Tse KP, Tsang NM, Chen KD, Li HP, Liang Y, Hsueh C, et al. MCP-1 promoter polymorphism at 2518 is associated with metastasis of nasopharyngeal carcinoma after treatment. Clin Cancer Res. 2007;13:6320–6.

    Article  CAS  PubMed  Google Scholar 

  20. Flores-Villanueva PO, Ruiz-Morales JA, Song CH, Flores LM, Jo EK, Montano M, et al. A functional promoter polymorphism monocyte chemoattractant protein-1 is associated with increased susceptibility to pulmonary tuberculosis. J Exp Med. 2005;202:1649–58.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Cho ML, Kim JY, Ko HJ, Kim YH, Kim WU, Cho CS, et al. The MCP-1 promoter -2518 polymorphism in Behcet’s disease: correlation between allele types, MCP-1 production and clinical symptoms among Korean patients. Autoimmunity. 2004;37:77–80.

    Article  CAS  PubMed  Google Scholar 

  22. Ioannidis JP, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP, et al. Effects of CCR5-Delta, 32, CCR2-64I, and SDF-1 3′A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med. 2001;135:782–95.

    Article  CAS  PubMed  Google Scholar 

  23. Miyagishi R, Niino M, Fukazawa T, Yabe I, Kikuchi S, Tashiro K. CC chemokine receptor 2 gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol. 2001;145:135–8.

    Article  Google Scholar 

  24. Zafiropoulos A, Crikas N, Passam AM, Spandidos DA. Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet. 2004;41:59.

    Article  Google Scholar 

  25. Coelho A, Matos A, Catarino R, Pinto D, Pereira D, Lopes C, et al. Protective role of the polymorphism CCR2-64I in the progression from squamous intraepithelial lesions to invasive cervical carcinoma. Gynecol Oncol. 2005;96:760–4.

    Article  CAS  PubMed  Google Scholar 

  26. Nakayama EE, Tanaka Y, Nagai Y, Iwamoto A, Shioda T. A CCR2 V64I polymorphism affects stability of CCR2A isoform. AIDS. 2004;18:729–38.

    Article  CAS  PubMed  Google Scholar 

  27. Dawson SJ, Morris PJ, Latchman DS. A single amino acid change converts an inhibitory transcription factor into an activator. J Biol Chem. 1996;271:11631–3.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Nephrology, Huizhou Municipal Central Hospital, 41 E Ling Bei Road, Huizhou, Guangdong, 516001, China

    Guan-Xian Liu

  2. Department of Internal Medicine, Shanghai East Hospital, Tongji University, Shanghai, China

    Xin Zhang & Su Li

  3. Faculty of Medicine, University of Toronto, 1 King’s College Circle, Toronto, Ontario, M5S1A8, Canada

    Richard D. Koiiche, Jerry H. Sindsceii & Haihan Song

Authors
  1. Guan-Xian Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Su Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard D. Koiiche
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jerry H. Sindsceii
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Haihan Song
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Guan-Xian Liu or Haihan Song.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, GX., Zhang, X., Li, S. et al. Monocyte chemotactic protein-1 and CC chemokine receptor 2 polymorphisms and prognosis of renal cell carcinoma. Tumor Biol. 34, 2741–2746 (2013). https://doi.org/10.1007/s13277-013-0827-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-0827-7

Keywords

Search

Navigation